# SER-155 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/ser-155

> The FDA approved SER-155, sponsored by Seres Therapeutics, Inc. (MCRB), on Apr 2023.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | SER-155 |
| Codes | SER-155 |
| Sponsor | Seres Therapeutics, Inc. (MCRB) https://sec-api.dev/companies/mcrb/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | breakthrough, fast track, orphan |

## Timeline

### Apr 2023: FDA approval

- Status: completed, approved. Date confidence: month.
- First seen 2025-01-13, last confirmed 2025-03-13.
- Press release filed with the SEC (EX-99) (accession 0001193125-25-053473): "Validated therapeutic modality and platform: Seres pioneered the development and FDA approval of VOWST as the first-ever oral live microbiome therapeutic DRAMATIC CLINICAL BENEFIT - Preventing infection recurrence Approximately 88% FDA approved (April 2023) to prevent the recurrence of sustained clinical response rate (C. diff. recurrence, at up to 8 weeks) C. difficile infection in adults VOWST asset sale (completed September 2024) provided capital to support pipeline advancement and resulted in a more streamlined, focused organization Source:" https://www.sec.gov/Archives/edgar/data/1609809/000119312525053473/d914751dex992.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-005011): "Validated therapeutic modality and platform: Seres pioneered the development and FDA approval of VOWST as the first-ever oral live microbiome therapeutic DRAMATIC CLINICAL BENEFIT - Preventing infection recurrence Approximately 88% FDA approved (April 2023) to prevent the recurrence of sustained clinical response rate (C. diff. recurrence, at up to 8 weeks) C. difficile infection in adults VOWST asset sale (completed September 2024) provided capital to support pipeline advancement and resulted in a more streamlined, focused organization Source:" https://www.sec.gov/Archives/edgar/data/1609809/000119312525005011/d923845dex991.htm

### Q2 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 1.
- First seen 2025-11-05, last confirmed 2026-03-12.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-103034): "Profile: SER-155 Status: Phase 1b Investigator sponsored trial, with readout expected Q2 2026 SER-155 irEC: Treat immune-related enterocolitis resulting from ICI therapies" https://www.sec.gov/Archives/edgar/data/1609809/000119312526103034/d98522dex992.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-103034): "Readout of investigator-sponsored SER-155 study in immune checkpoint-related enterocolitis, a frequent and serious side effect in cancer patients treated with immune checkpoint inhibitors, on track for Q2 2026" https://www.sec.gov/Archives/edgar/data/1609809/000119312526103034/d98522dex991.htm
- SEC Form 10-Q (accession 0001193125-25-266011): "Enrollment in the study is ongoing and is expected to complete by the end of 2025 with a clinical readout expected in early 2026." https://www.sec.gov/Archives/edgar/data/1609809/000119312525266011/mcrb-20250930.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/ser-155.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "SER-155 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/ser-155

```bibtex
@misc{secapidev_pdufa_ser_155_20261116,
  title        = {SER-155 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/ser-155}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_ser_155_20261116","title":"SER-155 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/ser-155","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
